Bioscreening specific peptide-expressing phage and its application in sensitive dual-mode immunoassay of SARS-CoV-2 spike antigen
Copyright © 2023 Elsevier B.V. All rights reserved..
Biorecognition components with high affinity and selectivity are vital in bioassay to diagnose and treat epidemic disease. Herein a phage display strategy of combining single-amplification-panning with non-amplification-panning was developed, by which a phage displaying cyclic heptapeptide ACLDWLFNSC (peptide J4) with good affinity and specificity to SARS-CoV-2 spike protein (SP) was identified. Molecular docking suggests that peptide J4 binds to S2 subunit by hydrogen bonding and hydrophobic interaction. Then the J4-phage was used as the capture antibody to establish phage-based chemiluminescence immunoassay (CLIA) and electrochemical impedance spectroscopy (EIS) analytical systems. The as-proposed dual-modal immunoassay platform exhibited good sensitivity and reliability in SARS-CoV-2 SP and pseudovirus assay. The limit of detection for SARS-CoV-2 SP by EIS immunoassay is 0.152 pg/mL, which is dramatically lower than that of 42 pg/mL for J4-phage based CLIA. Further, low to 40 transducing units (TU)/mL, 10 TU/mL SARS-CoV-2 pseudoviruses can be detected by the proposed J4-phage based CLIA and electrochemical immunosensor, respectively. Therefore, the as-developed dual mode immunoassays are potential methods to detect SARS-CoV-2. It is also expected to explore various phages with specific peptides to different targets for bioanalysis.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2024 2023 |
|---|---|
| Publication: |
2024 |
| Contained In: |
To Main Record - volume:266 |
|---|---|
| Contained In: |
Talanta - 266(2023), Pt 2 vom: 01. Jan., Seite 125093 |
| Language: |
English |
|---|
| Contributors: |
Pang, Shuang [Author] |
|---|
| Links: |
|---|
| Keywords: |
EIS immunoassay |
|---|
| Notes: |
Date Completed 15.09.2023 Date Revised 15.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.talanta.2023.125093 |
|---|
| funding: |
|
|---|---|
| Supporting institution / Project title: |
|
| PPN (Catalogue-ID): |
NLM361177631 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361177631 | ||
| 003 | DE-627 | ||
| 005 | 20230915232146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230824s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.talanta.2023.125093 |2 doi | |
| 028 | 5 | 2 | |a pubmed23n1474.xml |
| 035 | |a (DE-627)NLM361177631 | ||
| 035 | |a (NLM)37611368 | ||
| 035 | |a (PII)S0039-9140(23)00844-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pang, Shuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioscreening specific peptide-expressing phage and its application in sensitive dual-mode immunoassay of SARS-CoV-2 spike antigen |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2023 | ||
| 500 | |a Date Revised 15.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Biorecognition components with high affinity and selectivity are vital in bioassay to diagnose and treat epidemic disease. Herein a phage display strategy of combining single-amplification-panning with non-amplification-panning was developed, by which a phage displaying cyclic heptapeptide ACLDWLFNSC (peptide J4) with good affinity and specificity to SARS-CoV-2 spike protein (SP) was identified. Molecular docking suggests that peptide J4 binds to S2 subunit by hydrogen bonding and hydrophobic interaction. Then the J4-phage was used as the capture antibody to establish phage-based chemiluminescence immunoassay (CLIA) and electrochemical impedance spectroscopy (EIS) analytical systems. The as-proposed dual-modal immunoassay platform exhibited good sensitivity and reliability in SARS-CoV-2 SP and pseudovirus assay. The limit of detection for SARS-CoV-2 SP by EIS immunoassay is 0.152 pg/mL, which is dramatically lower than that of 42 pg/mL for J4-phage based CLIA. Further, low to 40 transducing units (TU)/mL, 10 TU/mL SARS-CoV-2 pseudoviruses can be detected by the proposed J4-phage based CLIA and electrochemical immunosensor, respectively. Therefore, the as-developed dual mode immunoassays are potential methods to detect SARS-CoV-2. It is also expected to explore various phages with specific peptides to different targets for bioanalysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EIS immunoassay | |
| 650 | 4 | |a Phage-CLIA | |
| 650 | 4 | |a SARS-CoV-2 SP | |
| 650 | 4 | |a SARS-CoV-2 pseudoviruses | |
| 650 | 4 | |a Specific peptide displayed phage | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Yu, Haipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yaru |e verfasserin |4 aut | |
| 700 | 1 | |a Jiao, Yiming |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Zongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mingyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haohan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Aihua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Talanta |d 1966 |g 266(2023), Pt 2 vom: 01. Jan., Seite 125093 |w (DE-627)NLM000143693 |x 1873-3573 |7 nnns |
| 773 | 1 | 8 | |g volume:266 |g year:2023 |g number:Pt 2 |g day:01 |g month:01 |g pages:125093 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.talanta.2023.125093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 936 | u | w | |d 266 |j 2023 |e Pt 2 |b 01 |c 01 |h 125093 |
| 951 | |a AR | ||
| 952 | |d 266 |j 2023 |e Pt 2 |b 01 |c 01 |h 125093 | ||